Literature DB >> 1084889

Human serum binding capacity and affinity for 25-hydroxyergocalciferol and 25-hydroxycholecalciferol.

J G Haddad, L Hillman, S Rojanasathit.   

Abstract

25-Hydroxyvitamin D-binding capacity and affinity were studied in human cord, adult, and maternal sera, and in sera from women receiving oral contraceptives, by in vitro satuaration analyses employing dextran-coated charcoal to adsorb unbound sterol. 25-Hydroxyergocalciferol and 25-hydroxycholecalciferol were equipotent in their ability to displace 3H 25-hydroxycholecalciferol from human serum binding sites. At 0C, the apparent dissociation constant for the serum binding of 25-hydroxycholecalciferol was low (Kd=8x 10-10M). Cord and adult sera had a similar 25-hydroxycholecalciferol binding capacity (1.8 x 10-6M), but the binding capacity of maternal sera and the sera from women receiving oral contraceptives was significantly higher. At physiological serum concentrations of 25-hydroxyvitamin D (5 x 10-8M), only 2-3% of human serum 25-hydroxyvitamin D-bindig sites are occupied.

Entities:  

Keywords:  Biology; Clinical Research; Contraception; Contraceptive Methods--side effects; Family Planning; Hormone Receptors; Human Volunteers; In Vitro; Membrane Proteins; Oral Contraceptives--side effects; Physiology; Research Methodology

Mesh:

Substances:

Year:  1976        PMID: 1084889     DOI: 10.1210/jcem-43-1-86

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

Review 1.  Clinical review: The role of the parent compound vitamin D with respect to metabolism and function: Why clinical dose intervals can affect clinical outcomes.

Authors:  Bruce W Hollis; Carol L Wagner
Journal:  J Clin Endocrinol Metab       Date:  2013-10-08       Impact factor: 5.958

Review 2.  Vitamin D administration during pregnancy as prevention for pregnancy, neonatal and postnatal complications.

Authors:  Carol L Wagner; Bruce W Hollis; Kalliopi Kotsa; Hana Fakhoury; Spyridon N Karras
Journal:  Rev Endocr Metab Disord       Date:  2017-09       Impact factor: 6.514

3.  Quantitative studies of the interaction of cholecalciferol ((vitamin D3) and its metabolites with different genetic variants of the serum binding protein for these sterols.

Authors:  M Kawakami; M Imawari; D S Goodman
Journal:  Biochem J       Date:  1979-05-01       Impact factor: 3.857

4.  Radioimmunoassay of the binding protein for vitamin D and its metabolites in human serum: concentrations in normal subjects and patients with disorders of mineral homeostasis.

Authors:  J G Haddad; J Walgate
Journal:  J Clin Invest       Date:  1976-11       Impact factor: 14.808

5.  Direct regional assignment of the gene for vitamin D binding protein (Gc-globulin) to human chromosome 4q11-q13 and identification of an associated DNA polymorphism.

Authors:  N E Cooke; H F Willard; E V David; D L George
Journal:  Hum Genet       Date:  1986-07       Impact factor: 4.132

6.  Determination of vitamin D and its metabolites in plasma from normal and anephric man.

Authors:  R M Shepard; R L Horst; A J Hamstra; H F DeLuca
Journal:  Biochem J       Date:  1979-07-15       Impact factor: 3.857

7.  Immunological and immunoassay studies of the binding protein for vitamin D and its metabolites in human serum.

Authors:  M Imawari; D S Goodman
Journal:  J Clin Invest       Date:  1977-03       Impact factor: 14.808

8.  Free 1,25-dihydroxyvitamin D levels in serum from normal subjects, pregnant subjects, and subjects with liver disease.

Authors:  D D Bikle; E Gee; B Halloran; J G Haddad
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

9.  Actin affinity chromatography in the purification of human, avian and other mammalian plasma proteins binding vitamin D and its metabolites (Gc globulins).

Authors:  J G Haddad; M A Kowalski; J W Sanger
Journal:  Biochem J       Date:  1984-03-15       Impact factor: 3.857

10.  Plasma binding capacity for 25-hydroxy-vitamin D in the elderly.

Authors:  W J MacLennan; J C Hamilton
Journal:  J Clin Pathol       Date:  1979-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.